Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mequitazine + pranlukast
- Development stage
- Preclinical
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of mequitazine, an H1-receptor antagonist (antihistamine), and pranlukast, a cysteinyl leukotriene receptor-1 antagonist. This combination may be used in the treatment of allergic rhinitis. Mequitazine helps alleviate symptoms such as sneezing, runny or stuffy nose, and itchy, watery eyes, while pranlukast works by antagonizing or reducing bronchospasm caused by allergic reactions by blocking the cysteinyl leukotriene receptor-1.
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)VRAC (Volume-regulated anion channel protein LRRC8A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on mequitazine + pranlukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mequitazine + pranlukast.